Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Signalling pathways in vasculogenic mimicry.
Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Paulis YW, et al. Among authors: soetekouw pm. Biochim Biophys Acta. 2010 Aug;1806(1):18-28. doi: 10.1016/j.bbcan.2010.01.001. Epub 2010 Jan 14. Biochim Biophys Acta. 2010. PMID: 20079807 Review.
CD44 enhances tumor aggressiveness by promoting tumor cell plasticity.
Paulis YW, Huijbers EJ, van der Schaft DW, Soetekouw PM, Pauwels P, Tjan-Heijnen VC, Griffioen AW. Paulis YW, et al. Among authors: soetekouw pm. Oncotarget. 2015 Aug 14;6(23):19634-46. doi: 10.18632/oncotarget.3839. Oncotarget. 2015. PMID: 26189059 Free PMC article.
Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, Keymeulen KB, Soetekouw PM, van Steensel MA, Mosterd K. Brinkhuizen T, et al. Among authors: soetekouw pm. J Am Acad Dermatol. 2014 Nov;71(5):1005-8. doi: 10.1016/j.jaad.2014.08.001. Epub 2014 Sep 4. J Am Acad Dermatol. 2014. PMID: 25199678 No abstract available.
Genetics and epigenetics of renal cell cancer.
Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruïne AP, van Engeland M. Baldewijns MM, et al. Among authors: soetekouw pm. Biochim Biophys Acta. 2008 Apr;1785(2):133-55. doi: 10.1016/j.bbcan.2007.12.002. Epub 2007 Dec 15. Biochim Biophys Acta. 2008. PMID: 18187049 Review.
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M. Leijen S, et al. Among authors: soetekouw pm. Cancer Chemother Pharmacol. 2011 Dec;68(6):1619-28. doi: 10.1007/s00280-011-1732-7. Epub 2011 Sep 28. Cancer Chemother Pharmacol. 2011. PMID: 21953275 Free PMC article. Clinical Trial.
VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP. Baldewijns MM, et al. Among authors: soetekouw pm. J Pathol. 2010 Jun;221(2):125-38. doi: 10.1002/path.2689. J Pathol. 2010. PMID: 20225241 Review.
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).
Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, Blank CU. Kelderman S, et al. Among authors: soetekouw pm. Acta Oncol. 2013 Nov;52(8):1786-8. doi: 10.3109/0284186X.2013.786839. Epub 2013 Apr 23. Acta Oncol. 2013. PMID: 23607756 No abstract available.
34 results